Digital Trials Digest, our quarterly newsletter
We know that a patient-centric approach to clinical trials generally leads to higher compliance and retention rates. DCTs are more convenient for participants.
In the first of our two-part series exploring minority participation in clinical trial research, we examine the numerous challenges to securing diversity in clinical trials and the consequences of primarily white patient populations.
ObvioHealth tackles misconceptions about decentralized clinical trials, they’re less safe, they’re always fully virtual, the data isn’t trustworthy, and so on.
BYOD ePRO models deliver a range of benefits to clinical trial stakeholders, including increased engagement, reduced site team burden, and more.
Digital therapeutics are playing an increasing role in mental health care. Ensuring that these DTx products meet quality thresholds is key to effective care.
When it comes to clinical trials, DCT and digital therapeutic (DTx) companies are natural partners. Both are tech savvy and adept in digital health
Decentralized clinical trials offer an effective avenue to mitigate the issues that typify pediatric clinical trials, including patient-reported data accuracy.
Though incidences of pneumonia have decreased overall, the disease is the leading infectious cause of death in children globally, affecting 1 in 6 child deaths.
In our conversations with trial sponsors, ObvioHealth often tackles common misconceptions about decentralized clinical trials (DCTs). These myths hinder our industry’s evolution by keeping sponsors from designing optimal trials that deliver better data with higher retention and compliance rates.